Efficacy evaluation of standardized dust mite allergen specific immunotherapy to patients of allergic rhinitis.
- Author:
Weiwei SONG
;
Xiaoping LIN
;
Ruonan CHAI
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antigens, Dermatophagoides;
administration & dosage;
Child;
Desensitization, Immunologic;
Female;
Follow-Up Studies;
Humans;
Male;
Middle Aged;
Rhinitis, Allergic;
therapy;
Treatment Outcome;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2014;28(5):300-302
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy of mite allergen specific immunotherapy (SIT) to patients of allergic rhinitis.
METHOD:A total of 102 patients with mite allergy were recruited into the study. They were randomly divided into two groups: SIT group (n = 51) and ST (symptomatic therapy) group (n = 51). They were given SIT with standardized allergen vaccine for 3 years or only symptomatic therapy respectively. Observation items include: rhinitis symptom scores, drug score, skin prick test result, serum specificity IgE (sIgE), peripheral eosinophil counting. The development of asthma and new allergens sensitization was also assessed.
RESULT:The blood eosinophil numbers, skin test index, rhinitis symptom scores and drug scores were all decreased significantly after the treatment with SIT for 3 years compared to that of ST group (P < 0.01). Although the level of serum slgE was decreased, no statistic diferences were found. No patients developed asthma in SIT group, and only 2.1% of patients had new allergen sensitization; 17.4% of those in ST group developed asthma, 32.6% had new sensitization. No severe adverse events occurred.
CONCLUSION:Keeping long-term SIT is effective and safe for patients with allergic rhinitis induced by mite, which can also prevent new allergen sensitization and development for asthma.
